Article
Virology
Maria Pokorska-Spiewak, Anna Dobrzeniecka, Magdalena Marczynska
Summary: This study analyzed the growth parameters in children treated with ledipasvir/sofosbuvir for chronic hepatitis C. The results showed that the treatment did not negatively affect the patients' growth. However, higher baseline body mass index scores were associated with more advanced liver fibrosis and steatosis in children with chronic hepatitis C.
Article
Gastroenterology & Hepatology
Mohamed El Kassas, Nermeen Abdeen, Dalia Omran, Mohamed Alboraie, Mohamed Salaheldin, Mohamed Eltabbakh, Rasha Farghaly, Mohammed Emadeldeen, Shimaa Afify, Ahmad Sweedy, Ahmed Ghalwash, Amr Abbass, Sameera Ezzat, Marwa Tahoon, Helmy M. ELshazly, Hassan Hamdy, Heba Omar
Summary: This study aimed to investigate the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients. The results showed acceptable SVR12 rates and safety profiles, with younger age having a significant positive association with treatment response.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Virology
Maria Pokorska-Spiewak, Anna Dobrzeniecka, Magdalena Marczynska
Summary: The study analyzed the one-year outcomes of children with chronic hepatitis C (CHC) treated with ledipasvir/sofosbuvir (LDV/SOF), showing that regression of liver fibrosis is possible in patients with cirrhosis but further observations are necessary to find predictors of fibrosis regression.
Article
Gastroenterology & Hepatology
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Jessica Tan, Kwong Ming Fock, Ngai Moh Law, Weiquan Li, Andrew Kwek, Yu Bin Tan, Jingyun Koh, Zheng Cong Lee, Loshini Senthil Kumar, Eng Kiong Teo, Tiing-Leong Ang
Summary: This study evaluated the efficacy and safety of sofosbuvir/velpatasvir with and without ribavirin in GT3 hepatitis C virus patients, indicating that this treatment option is safe and effective in a real-world setting, especially for decompensated GT3 patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kohei Kotani, Masaru Enomoto, Sawako Uchida-Kobayashi, Akihiro Tamori, Yoshimi Yukawa-Muto, Naoshi Odagiri, Hiroyuki Motoyama, Ritsuzo Kozuka, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Ken Kageyama, Akira Yamamoto, Atsushi Yoshida, Shigeaki Higashiyama, Joji Kawabe, Norifumi Kawada
Summary: In patients with decompensated hepatitis C-related cirrhosis, achieving sustained virologic response (SVR24) with SOF/VEL treatment can improve hepatocyte function and portal hypertension on short-term follow-up.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Andre Goemer, Mara Kloehn, Michelle Jagst, Maximilian K. Nocke, Sven Pischke, Thomas Horvatits, Julian Schulze zur Wiesch, Tobias Mueller, Svenja Hardtke, Markus Cornberg, Heiner Wedemeyer, Patrick Behrendt, Eike Steinmann, Daniel Todt
Summary: Chronic HEV infections are a significant issue in immunocompromised patients due to the absence of specifically approved antiviral drugs. A 24-week trial evaluated the efficacy of the nucleotide analog sofosbuvir in treating chronically HEV-infected patients, revealing the emergence of variants with lower sensitivity to the drug.
Article
Immunology
Timothy Papaluca, Stuart K. Roberts, Simone Strasser, Katherine A. Stuart, Geoffrey Farrell, Gerry MacQuillan, Gregory J. Dore, Amanda J. Wade, Jacob George, Simon Hazeldine, James O'Beirne, Alan Wigg, Leslie Fisher, Bruce McGarity, Rohit Sawhney, Marie Sinclair, James Thomas, Ivan Valiozis, Martin Weltman, Mark Wilson, Aidan Woodward, Golo Ahlenstiel, Mazhar Haque, Miriam Levy, Emily Prewett, William Sievert, Siddharth Sood, Edmund Tse, Zina Valaydon, Scott Bowden, Mark Douglas, Kate New, Jacinta O'Keefe, Margaret Hellard, Joseph Doyle, Mark Stoove, Alexander J. Thompson
Summary: This real-world study confirms the high efficacy of SOF/VEL/VOX for difficult-to-cure NS5A inhibitor experienced patients, particularly those with GT3 and cirrhosis, with an SVR12 rate of 85%. Treatment was generally well tolerated, but serious adverse events may occur in patients with advanced liver disease.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Yoshinari Takaoka, Kouichi Miura, Naoki Morimoto, Tadashi Ikegami, Satoru Kakizaki, Ken Sato, Takashi Ueno, Atsushi Naganuma, Takashi Kosone, Hirotaka Arai, Takeshi Hatanaka, Toshiyuki Tahara, Shigeo Tano, Takaaki Ohtake, Toshimitsu Murohisa, Masashi Namikawa, Takeharu Asano, Toshiro Kamoshida, Katsuhiko Horiuchi, Takeshi Nihei, Atsuko Soeda, Hidekazu Kurata, Takeshi Fujieda, Toshiya Ohtake, Yukimura Fukaya, Makoto Iijima, Shunji Watanabe, Norio Isoda, Hironori Yamamoto
Summary: In this study, 12-week sofosbuvir/velpatasvir treatment was found to be relatively safe and effective for patients with decompensated cirrhosis, significantly improving liver function in the majority of patients. However, the presence of large portosystemic shunt and hyperbilirubinemia were identified as independent factors that interfered with the improvement in the CP score.
HEPATOLOGY RESEARCH
(2021)
Article
Infectious Diseases
Yilihamu Abulitifu, Jiangshan Lian, Munire Adilijiang, Lan Liu, Fengcong Zhao, Wen Qian, Yongping Zhang
Summary: This study investigated the effectiveness and safety of sofosbuvir-velpatasvir (SOF/VEL) with and without ribavirin (RBV) in patients with genotype 3 (GT3) hepatitis C virus (HCV) infection-related cirrhosis from Xinjiang, China. The results showed that SOF/VEL, with or without RBV, was effective and safe for the treatment of GT3 HCV-associated cirrhosis.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Medicine, General & Internal
Qiao Yang, Yifan Tong, Borui Pi, Hong Yu, Fangfang Lv
Summary: Metabolic factors, including diabetes and low levels of high-density lipoprotein cholesterol (HDLC), are risk factors for bacterial infections in patients with hepatitis B virus (HBV)-related cirrhosis, and their coexistence leads to a higher risk.
FRONTIERS IN MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Cih-En Huang, Jung-Jung Chang, Yu-Ying Wu, Shih-Hao Huang, Wei-Ming Chen, Chia-Chen Hsu, Chang-Hsien Lu, Chao-Hung Hung, Chung-Sheng Shi, Kuan-Der Lee, Chih-Cheng Chen, Min-Chi Chen
Summary: This study compared the different risk factors and impacts of hepatitis C virus-associated thrombocytopenia (HCV-TP) and hepatitis B virus-associated thrombocytopenia (HBV-TP). The findings showed that the incidence of thrombocytopenia was higher in HCV patients compared to HBV patients. Additionally, the risk factors for thrombocytopenia varied with the severity and virus type, suggesting the need for different management approaches for HCV-TP and HBV-TP.
BIOMEDICAL JOURNAL
(2022)
Article
Public, Environmental & Occupational Health
Hussein A. AbdEl-maksoud, Mohamed G. Elharrif, Omnia Abd El-hamid, Saad M. Alsaab, Eman M. El-sorady
Summary: The study monitored iron, lipid, and liver profiles in hepatitis C patients before and during treatment with sofosbuvir antiviral drug. Results showed significant improvement in serum iron, cholesterol, and other parameters, while serum ferritin, transferrin, and other indicators increased significantly after treatment with sofosbuvir, indicating amelioration of disruption caused by hepatitis C virus infection.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)
Article
Nutrition & Dietetics
Yue Yin, Yiling Li, Lichun Shao, Shanshan Yuan, Bang Liu, Su Lin, Yida Yang, Shanhong Tang, Fanping Meng, Yunhai Wu, Yu Chen, Bimin Li, Qiang Zhu, Xingshun Qi
Summary: The study showed that overweight/obesity is modestly associated with long-term survival in patients with cirrhosis but not an independent prognostic predictor. Overweight/obesity has little effect on the short-term survival of patients with cirrhosis and acute gastrointestinal bleeding. There was no significant difference in long-term survival rate between underweight and normal weight groups in both parts of the study.
FRONTIERS IN NUTRITION
(2021)
Article
Gastroenterology & Hepatology
Hartwig Klinker, Uwe Naumann, Martin Roessle, Thomas Berg, Mark Bondin, Kristina Lohmann, Bettina Koenig, Stefan Zeuzem, Markus Cornberg
Summary: In this real-world analysis, the 8-week glecaprevir/pibrentasvir therapy showed high sustained virologic response rates and good tolerability in patients with compensated cirrhosis due to chronic hepatitis C, with rare adverse events leading to treatment discontinuation.
LIVER INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
Steve Leumi, Mingzhe Guo, Jie Lu, Zhaoning Wang, Tianyu Gan, Lin Han, Jackline Ngari, Yimin Tong, Xiaogang Xiang, Qing Xie, Lanfeng Wang, Jin Zhong
Summary: Despite the excellent antiviral potency of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), drug-resistant viral mutations remain a potential challenge. This study identified the combination of two NS5B mutations, S282T and K74R, as a novel resistance-associated substitution (RAS) that confers substantial resistance to SOF while retaining the HCV replication capacity.
ANTIVIRAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Hiroyuki Suzuki, Hitomi Sezaki, Fumitaka Suzuki, Kayoko Kasuya, Tomoya Sano, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Masahiro Kobayashi, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Hiromitsu Kumada
HEPATOLOGY RESEARCH
(2019)
Article
Gastroenterology & Hepatology
Keiji Yokoyama, Makoto Irie, Naoaki Tsuchiya, Eri Yamauchi, Motoko Kawashima, Takashi Miyayama, Hiromi Fukuda, Ryo Yamauchi, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Summary: The study indicated that irsogladine maleate may improve gastric mucosa in patients with PHG by restoring the tight junction protein claudin-3.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Oncology
Hideo Kunimoto, Satoshi Shakado, Takashi Tanaka, Kazuhide Takata, Ryo Yamauchi, Hiromi Fukuda, Naoaki Tsuchiya, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Fumihito Hirai, Shotaro Sakisaka
Article
Oncology
Takashi Tanaka, Kazuhide Takata, Hideo Kunimoto, Hiromi Fukuda, Ryo Yamauchi, Naoaki Tsuchiya, Shinjiro Inomata, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Article
Biology
Tomoya Sano, Takumi Kawaguchi, Tatsuya Ide, Keisuke Amano, Reiichiro Kuwahara, Teruko Arinaga-Hino, Takuji Torimura
Summary: Nucle(t)ide analogs are effective for chronic hepatitis B, but can lead to renal dysfunction in long-term use. Switching to newer agents like tenofovir alafenamide may be a safe and effective strategy for managing renal tubular dysfunction in these patients.
Article
Oncology
Kazuhide Takata, Takashi Tanaka, Akira Anan, Atsushi Fukunaga, Takahiro Nagata, Hiromi Fukuda, Ryo Yamauchi, Hideo Kunimoto, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Kaoru Iwata, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Summary: This study retrospectively analyzed 167 patients with hepatocellular carcinoma (HCC) and compared the effects of radiofrequency ablation (RFA) plus percutaneous ethanol injection (PEI) versus RFA monotherapy on local tumor progression (LTP) in perivascular HCC. The results showed that the combination therapy significantly reduced the LTP rate compared to RFA monotherapy.
Review
Nutrition & Dietetics
Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Summary: Fatty liver is associated with extra-hepatic diseases and can impact patients' prognosis and quality of life. Metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed as a new definition for fatty liver, with the aim of identifying patients at high risk of extra-hepatic complications. This review focuses on the relationships between MAFLD and multi-organ diseases, as well as the pathogenic mechanisms of inter-organ crosstalk.
Article
Gastroenterology & Hepatology
Takahiro Nagata, Sadahiro Funakoshi, Daisuke Morihara, Satoshi Shakado, Keiji Yokoyama, Kazuhide Takata, Takashi Tanaka, Atsushi Fukunaga, Ryo Yamauchi, Hiromi Fukuda, Hiroki Matsuoka, So Imakiire, Hideto Sakisaka, Satoshi Matsuoka, Nobuaki Kuno, Koichi Abe, Hideki Ishibashi, Shinya Ashizuka, Fumihito Hirai
Summary: The study aimed to clarify the characteristics of nonalcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD). The results showed that worsening nutritional and inflammatory status in IBD patients is associated with complications of NAFLD. CT imaging for diagnosing NAFLD in IBD patients may be useful for early detection and assessing the need for therapeutic intervention.
INTESTINAL RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Tomoya Sano, Keisuke Amano, Tatsuya Ide, Hiroshi Isoda, Yuichi Honma, Yasuyo Morita, Yoichi Yano, Hiroki Nakamura, Satoshi Itano, Ichiro Miyajima, Miki Shirachi, Reiichiro Kuwahara, Miki Ohno, Toshihiro Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Teruko Arinaga-Hino, Machiko Kawaguchi, Yuichiro Eguchi, Takuji Torimura, Hirokazu Takahashi, Masaru Harada, Takumi Kawaguchi
Summary: The study aimed to evaluate the impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the development of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication. Results showed that MASLD at 24 weeks of sustained virological response was an independent risk factor for HCC development in elderly patients with HCV eradication. The decision tree analysis revealed that MASLD was associated with HCC development, even in patients with low serum AFP levels.
HEPATOLOGY RESEARCH
(2023)
Article
Medicine, General & Internal
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Summary: This study investigated the long-term efficacy of rifaximin (RFX) in treating hyperammonemia and refractory ascites in patients with cirrhosis. The results showed that RFX administration led to a decrease in blood ammonia levels and improvement in hepatic spare ability and quality of life up to 36 months. Additionally, RFX treatment showed efficacy in improving refractory ascites, and renin concentration may be a predictive marker for assessing ascites control.
MEDICINA-LITHUANIA
(2022)
Article
Gastroenterology & Hepatology
Keiji Yokoyama, Takashi Miyayama, Yotaro Uchida, Hiromi Fukuda, Ryo Yamauchi, Naoaki Tsuchiya, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Summary: DFV-EUS has significant advantages in the treatment of GV by providing real-time endoscopic and ultrasound views during sclerosant delivery. Further research is needed to clarify the proper use of ultrasound views for safer and more effective therapy. In cases where there is a distance between the mucosal surface and vascular lumen or when additional puncture is needed for blood flow, DFV-EUS could be a good option for GV treatment.
CASE REPORTS IN GASTROENTEROLOGY
(2021)
Article
Medicine, General & Internal
Keiji Yokoyama, Eri Yamauchi, Yotaro Uchida, Takanori Kitaguchi, Hiromi Fukuda, Ryo Yamauchi, Naoaki Tsuchiya, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Shinjiro Inomata, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
CLINICAL CASE REPORTS
(2020)
Article
Gastroenterology & Hepatology
Yi-Ling Ko, Kazuhide Takata, Takashi Tanaka, Jun Ohishi, Morishige Takeshita, Ryo Yamauchi, Hiromi Fukuda, Takashi Miyayama, Yotaro Uchida, Keiji Yokoyama, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
CASE REPORTS IN GASTROENTEROLOGY
(2020)